ARTICLE | Company News
Amgen, Immatics in bispecifics deal
January 10, 2017 12:30 AM UTC
Amgen Inc. (NASDAQ:AMGN) and Immatics Biotechnologies GmbH (Tuebingen, Germany) partnered to develop T cell engaging bispecific immunotherapies to treat cancer.
Immatics is to receive $30 million up front and is eligible for more than $500 million in milestones for each program, plus tiered royalties...